Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 636157, 7 pages
http://dx.doi.org/10.1155/2012/636157
Review Article

Macrolide Therapy in Chronic Inflammatory Diseases

Department of Early Diagnosis of Arthritis, Institute of Rheumatology, Spartanska 1, 02-627 Warsaw, Poland

Received 20 January 2012; Revised 13 July 2012; Accepted 16 July 2012

Academic Editor: Kazuhito Asano

Copyright © 2012 Brygida Kwiatkowska and Maria Maślińska. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. N. Alekshun, “New advances in antibiotic development and discovery,” Expert Opinion on Investigational Drugs, vol. 14, no. 2, pp. 117–134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. N. Wilson, “The A-Z of bacterial translation inhibitors,” Critical Reviews in Biochemistry and Molecular Biology, vol. 44, pp. 393–433, 2009. View at Publisher · View at Google Scholar
  3. S. Douthwaite, L. H. Hansen, and P. Mauvais, “Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA,” Molecular Microbiology, vol. 36, no. 1, pp. 183–192, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. B.G Macrolides Katzung, Basic & Clinical Pharmacology, vol. 44, 9th edition, 2004.
  5. H. Suzaki, K. Asano, S. Ohki, K. Kanai, T. Mizutani, and T. Hisamitsu, “Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo,” Mediators of Inflammation, vol. 8, no. 4-5, pp. 199–204, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Shimane, K. Asano, M. Suzuki, T. Hisamitsu, and H. Suzaki, “Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro,” Mediators of Inflammation, vol. 10, no. 6, pp. 323–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Schultz, P. Speelman, C. E. Hack, W. A. Buurman, S. J. H. Van Deventer, and T. Van Der Poll, “Intravenous infusion of eryhtromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae,” Journal of Antimicrobial Chemotherapy, vol. 46, no. 2, pp. 235–240, 2000. View at Google Scholar · View at Scopus
  8. N. Matsuoka, K. Eguchi, A. Kawakami et al., “Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells,” Clinical and Experimental Immunology, vol. 104, no. 3, pp. 501–508, 1996. View at Google Scholar · View at Scopus
  9. H. Takizawa, M. Desaki, T. Ohtoshi et al., “Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells,” American Journal of Respiratory and Critical Care Medicine, vol. 156, no. 1, pp. 266–271, 1997. View at Google Scholar · View at Scopus
  10. S. Nelson, W. R. Summer, P. B. Terry, G. A. Warr, and G. J. Jakab, “Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung,” American Review of Respiratory Disease, vol. 136, no. 5, pp. 1207–1212, 1987. View at Google Scholar · View at Scopus
  11. N. Keicho, S. Kudoh, H. Yotsumoto, and K. S. Akagawa, “Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A,” Journal of Antibiotics, vol. 46, no. 9, pp. 1406–1413, 1993. View at Google Scholar · View at Scopus
  12. N. Keicho, S. Kudoh, H. Yotsumto, and K. S. Akagawa, “Erythromycin promotes monocyte to macrophage differentiation,” Journal of Antibiotics, vol. 47, no. 1, pp. 80–89, 1994. View at Google Scholar · View at Scopus
  13. K. Yamamoto, T. Arakawa, N. Ueda, and S. Yamamoto, “Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells,” The Journal of Biological Chemistry, vol. 270, no. 52, pp. 31315–31320, 1995. View at Google Scholar · View at Scopus
  14. A. Ianaro, A. Ialenti, P. Maffia et al., “Anti-inflammatory activity of macrolide antibiotics,” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 1, pp. 156–163, 2000. View at Google Scholar · View at Scopus
  15. T. Kohyama, H. Takizawa, S. Kawasaki, N. Akiyama, M. Sato, and K. Ito, “Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 4, pp. 907–911, 1999. View at Google Scholar · View at Scopus
  16. E. Sato, D. K. Nelson, S. Koyama, J. C. Hoyt, and R. A. Robbins, “Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 2, pp. 401–406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. A. C. Williams, H. F. Galley, A. M. Watt, and N. R. Webster, “Differential effects of three antibiotics on T helper cell cytokine expression,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 3, pp. 502–506, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Sugiyama, R. Shirai, H. Mukae et al., “Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells,” Clinical and Experimental Immunology, vol. 147, no. 3, pp. 540–546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Kanoh and B. K. Rubin, “Mechanisms of action and clinical application of macrolides as immunomodulatory medications,” Clinical Microbiology Reviews, vol. 23, no. 3, pp. 590–615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Nakamura, S. Fujishima, T. Inoe et al., “Clinical and immunomodulatory effects of roxitromycin therapy for chronic respiratory tract infection,” European Respiratory Society, vol. 13, pp. 1371–1379, 1999. View at Publisher · View at Google Scholar
  21. K. Aoshiba, A. Nagai, and K. Konno, “Erythromycin shortens neutrophil survival by accelerating apoptosis,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 4, pp. 872–877, 1995. View at Google Scholar · View at Scopus
  22. K. Inamura, N. Ohta, S. Fukase, N. Kasajima, and M. Aoyagi, “The effects of erythromycin on human peripheral neutrophil apoptosis,” Rhinology, vol. 38, no. 3, pp. 124–129, 2000. View at Google Scholar · View at Scopus
  23. T. Oyama, T. Sakuta, K. Matsushita, I. Maruyama, S. Nagaoka, and M. Torii, “Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture,” Journal of Periodontology, vol. 71, no. 10, pp. 1546–1553, 2000. View at Google Scholar · View at Scopus
  24. T. Fumimori, S. Honda, K. Migita et al., “Erythromycin suppresses the expression of cyclooxygenase-2 in rheumatoid synovial cells,” Journal of Rheumatology, vol. 31, no. 3, pp. 436–441, 2004. View at Google Scholar · View at Scopus
  25. H. Terao, K. Asano, K. I. Kanai et al., “Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice,” Mediators of Inflammation, vol. 12, no. 4, pp. 195–202, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kohri, J. Tamaoki, M. Kondo, K. Aoshiba, E. Tagaya, and A. Nagai, “Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages,” European Respiratory Journal, vol. 15, no. 1, pp. 62–67, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. K. W. Garry, I. Rubinstein, M. H. Gotfried, I. J. Khan, S. Varma, and L. H. Danziger, “Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma,” Chest, vol. 118, no. 6, pp. 1826–1827, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Shinkai, M. O. Henke, and B. K. Rubin, “Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action,” Pharmacology and Therapeutics, vol. 117, no. 3, pp. 393–405, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Keicho and S. Kudoch, “Diffuse panbronchiolotis:role of macrolides therapy,” American Journal of Respiratory Medicine, vol. 1, no. 2, pp. 119–131, 2002. View at Google Scholar
  30. T. Enomoto, A. Azuma, K. Sakakibara, J. Usuki, and S. Kudo, “Azithromycin therapy for patients with intractable diffuse panbronchiolitis,” The Japanese journal of antibiotics, vol. 56, supplement A, pp. 12–14, 2003. View at Google Scholar · View at Scopus
  31. B. M. Vanaudenaerde, R. Vos, I. Meyts et al., “Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back,” Inflammation and Allergy, vol. 7, no. 4, pp. 279–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. L. M. Gianni and M. M. Sulli, “Topical tacrolimus in the treatment of atopic dermatitis,” Annals of Pharmacotherapy, vol. 35, no. 7-8, pp. 943–946, 2001. View at Google Scholar · View at Scopus
  33. R. F. Standaert, A. Galat, G. L. Verdine, and S. L. Schreiber, “Molecular cloning and overexpression of the human FK506-binding protein FKBP,” Nature, vol. 346, no. 6285, pp. 671–674, 1990. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Nghiem, G. Pearson, and R. G. Langley, “Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis,” Journal of the American Academy of Dermatology, vol. 46, no. 2, pp. 228–241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Komine and K. Tamaki, “An open trial of oral macrolide treatment for psoriasis vulgaris,” Journal of Dermatology, vol. 27, no. 8, pp. 508–512, 2000. View at Google Scholar · View at Scopus
  36. M. Polat, N. Lenk, B. Yalcin et al., “Efficacy of erythromycin for psoriasis vulgaris,” Clinical and Experimental Dermatology, vol. 32, no. 3, pp. 295–297, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. G. P. H. Gui, P. R. S. Thomas, M. L. V. Tizard, J. Lake, J. D. Sanderson, and J. Hermon-Taylor, “Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics,” Journal of Antimicrobial Chemotherapy, vol. 39, no. 3, pp. 393–400, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Inoue, H. Nakase, M. Matsuura et al., “Open label trial of claritromycin therapy in Japanese patients with Crohn's disease,” Journal of Gastroenterology and Hepatology, vol. 22, p. 984, 2007. View at Publisher · View at Google Scholar
  39. S. K. Chuah, F. W. Tsay, P. I. Hsu, and D. C. Wu, “A new look at anti-Helicobacter pylori therapy,” World Journal of Gastroenterology, vol. 17, no. 35, pp. 3971–3975, 2011. View at Google Scholar
  40. Z. Itoh, T. Suzuki, and M. Nakaya, “Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut,” Antimicrobial Agents and Chemotherapy, vol. 26, no. 6, pp. 863–869, 1984. View at Google Scholar · View at Scopus
  41. S. M. Catnach and P. D. Fairclough, “Erythromycin and the gut,” Gut, vol. 33, no. 3, pp. 397–401, 1992. View at Google Scholar · View at Scopus
  42. H. Mentec, H. Dupont, M. Bocchetti, P. Cani, F. Ponche, and G. Bleichner, “Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications,” Critical Care Medicine, vol. 29, no. 10, pp. 1955–1961, 2001. View at Google Scholar · View at Scopus
  43. C. V. Hawkyard and R. J. Koerner, “The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks,” Journal of Antimicrobial Chemotherapy, vol. 59, no. 3, pp. 347–358, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. D. E. Furst, K. Saag, M. R. Fleischmann et al., “Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study,” Arthritis and Rheumatism, vol. 46, no. 8, pp. 2020–2028, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Migita, K. Eguchi, T. Aoyagi et al., “The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast,” Clinical and Experimental Immunology, vol. 104, no. 1, pp. 86–91, 1996. View at Google Scholar · View at Scopus
  46. M. Ogrendik, “Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial,” Clinical Therapeutics, vol. 31, no. 8, pp. 1754–1764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Ogrednik, “Effects of clarithromycin in patients with active rheumatoid arthritis,” Current Medical Research and Opinion, vol. 23, pp. 515–522, 2007. View at Publisher · View at Google Scholar
  48. M. Ogrendik and N. Karagoz, “Treatment of rheumatoid arthritis with roxithromycin: a randomized trial,” Postgraduate Medicine, vol. 123, pp. 220–227, 2011. View at Publisher · View at Google Scholar
  49. J. D. Carter, J. Valeriano, and F. B. Vasey, “Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison,” Journal of Rheumatology, vol. 31, no. 10, pp. 1973–1980, 2004. View at Google Scholar · View at Scopus
  50. U. Dreses-Werringloer, I. Padubrin, H. Zeidler, and L. Köhler, “Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 11, pp. 3001–3008, 2001. View at Publisher · View at Google Scholar · View at Scopus
  51. X. X. Bin, K. Wolf, T. Schaffner, and R. Malinverni, “Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 6, pp. 1761–1764, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. F. Denis, C. Chaumeil, P. Goldschmidt et al., “Microbiological efficacy of 3-day treatment with azithromycin 1.5% eyedrops for purulent bacterial conjunctivitis,” European Journal of Ophthalmology, vol. 18, no. 6, pp. 858–868, 2008. View at Google Scholar · View at Scopus
  53. S. K. West, B. Munoz, H. Mkocha, C. A. Gaydos, and T. C. Quinn, “Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania,” Journal of Infectious Diseases, vol. 204, no. 2, pp. 268–273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. J. Jang, H. J. Kwon, and B. J. Lee, “Effect of clarithromycin on rhinovirus-16 infection in A549 cells,” European Respiratory Journal, vol. 27, no. 1, pp. 12–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Suzuki, M. Yamaya, K. Sekizawa et al., “Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells,” American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 8, pp. 1113–1118, 2002. View at Google Scholar · View at Scopus
  56. A. Beigelman, C. L. Mikols, S. P. Gunsten, C. L. Cannon, S. L. Brody, and M. J. Walter, “Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis,” Respiratory Research, vol. 11, article 90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Yamaya, K. Shinya, Y. Hatachi et al., “Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 1, pp. 81–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. H. J. Eisen, E. M. Tuzcu, R. Dorent et al., “Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients,” The New England Journal of Medicine, vol. 349, no. 9, pp. 847–858, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Mencarelli, E. Distrutti, B. Renga et al., “Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis,” European Journal of Pharmacology, vol. 665, no. 1–3, pp. 29–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. M.V Progeria Blagosklonny, “Rapamycin and normal aging: recent breakthrough,” AGING, vol. 3, no. 7, pp. 685–691, 2011. View at Google Scholar
  61. P. M. Gascon and P. Dayer, “Comparative effects of macrolide antibiotics on liver mono-oxygenases. Abstract,” Clinical Pharmacology & Therapeutics, vol. 49, p. 158, 1991. View at Google Scholar
  62. N. A. Von Rosenstiel and D. Adam, “Macrolide antibacterials: drug interactions of clinical significance,” Drug Safety, vol. 13, no. 2, pp. 105–122, 1995. View at Google Scholar · View at Scopus
  63. J. F. Westphal, “Macrolide-Induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin,” British Journal of Clinical Pharmacology, vol. 50, no. 4, pp. 285–295, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Gomes, M. M. Mamdani, and D. N. Juurlink, “Macrolide-induced digoxin toxicity: a population-based study,” Clinical Pharmacology and Therapeutics, vol. 86, no. 4, pp. 383–386, 2009. View at Publisher · View at Google Scholar · View at Scopus